Distinguished in Autism Spectrum Disorder

Xiaoyan Y. Ke-Yang

49 North. Huayuan Road, 
Huayuan, CN 
Distinguished in Autism Spectrum Disorder
49 North. Huayuan Road, 
Huayuan, CN 
OverviewLocationsClinical Research

Overview

Xiaoyan Ke-Yang practices in Huayuan, China. Ke-Yang is rated as a Distinguished expert by MediFind in the treatment of Autism Spectrum Disorder. Their top areas of expertise are Autism Spectrum Disorder, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Marginal Zone Lymphoma (MZL), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 231 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 67 articles in the study of Autism Spectrum Disorder.

Locations

49 North. Huayuan Road, Huayuan, 100191, China
Other Locations
264 GuangZhou Road, Nanjing, 210029, China
49 Huayuan North Road, Haidian, 100191, China
GuangZhou Road 264#, Nanjing, 210029, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Zanubrutinib
Study Phase: Phase 2
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
View 3 Less Clinical Trials

231 Total Publications

[Retracted] Treatment with a selenium-platinum compound induced T-cell acute lymphoblastic leukemia/lymphoma cells apoptosis through the mitochondrial signaling pathway.
[Retracted] Treatment with a selenium-platinum compound induced T-cell acute lymphoblastic leukemia/lymphoma cells apoptosis through the mitochondrial signaling pathway.
Journal: Oncology letters
Published: October 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ke-Yang's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile